Printer Friendly
The Free Library
14,717,670 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Amgen dispute.


Investors and analysts aren't entirely sure that Amgen will be entirely successful in fighting off a threat to its blockbuster anemia drug Epogen.

The Thousand Oaks Thousand Oaks, residential city (1990 pop. 104,352), Ventura co., S Calif., in a farm area; inc. 1964. Avocados, citrus, vegetables, strawberries, and nursery products are grown.  biotech bi·o·tech  
n. Informal
Biotechnology.


biotech
Noun

short for biotechnology

Noun 1.
 giant is fighting against Roche Holdings AG, which is importing pegylated recombinant human erythropoietin erythropoietin /eryth·ro·poi·e·tin/ (-poi´e-tin) a glycoprotein hormone secreted by the kidney in the adult and by the liver in the fetus, which acts on stem cells of the bone marrow to stimulate red blood cell production  called Cera, which is used to increase red blood cell counts red blood cell count,
n the number of red blood cells (erthrocytes) in 1 mm3 of blood; a useful diagnostic tool in the determination of several kinds of anemia. See also mean corpuscular hemoglobin.
. Amgen claims the company is violating Amgen's patents and argued against the importation in the U.S. District Court of Massachusetts.

A Merill Lynch analyst wrote that he thinks it is unlikely that a judge will dismiss the case, and that it could drag potentially into 2007. Cera has not yet been approved for use either in Europe or the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. .

The U.S. International Trade Commission also said that it would look into Amgen's claims. Aranesp, another Amgen product, is a longer-lasting version of Epogen, and the drugs combined to generate $6 billion in sales for the company last year.
COPYRIGHT 2006 CBJ, L.P.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Public Companies
Author:Colburn, Jonathan D.
Publication:San Fernando Valley Business Journal
Date:May 22, 2006
Words:154
Previous Article:Health Net triples profits.(Public Companies)
Next Article:WellPoint.(Anthem Blue Cross and Blue Shield launches new health insurance service)(Brief article)
Topics:



Related Articles
Amgen Wins infringement Suit.(Brief Article)(Statistical Data Included)
EARLY RULING FAVORS AMGEN JUDGE FINDS PATENT INFRINGED.(Business)
STRONG AMGEN EARNINGS EXPECTED; NEWS KEEPS SHARES RISING.(Business)
AMGEN TOPS EXPECTATIONS OF ANALYSTS.(Business)(Statistical Data Included)
AMGEN ORDERED TO PAY $205 MILLION.(BUSINESS)
AMGEN RIVALS GET OK FOR DRUG TESTING.(Business)
AMGEN SALES UP IN BUMPY QUARTER.(Business)
Drug settlement.(Review & preview: August 22-28)(Amgen Inc. settles patent dispute with Genentech Inc.)(Brief Article)
AMGEN SUES OVER EPOGEN THREE UNITS OF ROCHE ACCUSED OF PATENT INFRINGEMENT.(Business)
Amgen case.(THE LABJ: Online Journal)(Roche Holding Ltd.)(Amgen Inc.)(Brief article)

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles